HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population by Bruijstens, A.L. (Arlette L.) et al.
ARTICLE OPEN ACCESS
HLA association in MOG-IgG– and AQP4-
IgG–related disorders of the CNS in the Dutch
population
Arlette L. Bruijstens, MD, Yu YiM.Wong,MD, PhD, Danie¨lle E. van Pelt, MD, PhD, Pieter J.E. van der Linden, BSc,
Geert W. Haasnoot, BSc, Rogier Q. Hintzen, MD, PhD, Frans H.J. Claas, PhD,* Rinze F. Neuteboom, MD, PhD,*
and Beatrijs H.A. Wokke, MD, PhD*
Neurol Neuroimmunol Neuroinflamm 2020;7:e702. doi:10.1212/NXI.0000000000000702
Correspondence
Dr. Bruijstens
a.bruijstens@erasmusmc.nl
Abstract
Objective
To investigate the possible human leukocyte antigen (HLA) association of both myelin oli-
godendrocyte glycoprotein (MOG-IgG)-associated diseases (MOGAD) and aquaporin-4
antibody (AQP4-IgG)-positive neuromyelitis optica spectrum disorders (NMOSDs) in the
Dutch population with European ancestry to clarify similarities or differences in the immu-
nogenetic background of both diseases.
Methods
Blood samples from patients in the Dutch national MS/NMOSD expert clinic were tested for
MOG-IgG and AQP4-IgG using a cell-based assay. HLA Class I and II genotyping was per-
formed in 43 MOG-IgG–seropositive and 42 AQP4-IgG–seropositive Dutch patients with
European ancestry and compared with those of 5,604 Dutch healthy blood donors.
Results
No significant HLA association was found in MOG-IgG–seropositive patients. The AQP4-
IgG–seropositive patients had a significant higher frequency of HLA-A*01 (61.9% vs 33.7%,
OR 3.16, 95% CI, 1.707–5.863, p after correction [pc] = 0.0045), HLA-B*08 (61.9% vs 25.6%,
OR 4.66, 95% CI, 2.513–8.643, pc < 0.0001), and HLA-DRB1*03 (51.2% vs 27.6%, OR 2.75,
95% CI, 1.495–5.042, pc = 0.0199) compared with controls.
Conclusions
The present study demonstrates differences in the immunogenetic background of MOGAD
and AQP4-IgG–positive NMOSD. The strong positive association with HLA-A*01, -B*08, and
-DRB1*03 is suggestive of a role of this haplotype in the etiology of AQP4-IgG–positive
NMOSD in patients with European ancestry, whereas in MOGAD no evidence was found for
any HLA association in these disorders.
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Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG)
are related to a spectrum of demyelinating syndromes of the
CNS, both in adult and pediatric patients. These are currently
known as MOG-IgG–associated diseases (MOGADs) and
predominantly include acute disseminated encephalomyelitis
(ADEM), optic neuritis (ON), and/or transverse myelitis
(TM).1–4 A subset of these patients seropositive for MOG-
IgG fulfill the criteria for neuromyelitis optica spectrum dis-
order (NMOSD),5 whereas the majority of NMOSDs are
associated with aquaporin-4 antibodies (AQP4-IgG).6–9 This
partial clinical overlap between patients seropositive for
MOG-IgG and AQP4-IgG is interesting because the un-
derlying disease mechanism is thought to be different, with
autoantibodies targeting oligodendrocytes and astrocytes,
respectively.10–12 The existence of these IgG autoantibodies,
however, is indicative for a key role for B and CD4+ T cells in
the disease process of both disorders and, consequently, for
a potential role for human leukocyte antigen (HLA).
Possible HLA associations could further elucidate similarity or
difference between MOG-IgG– and AQP4-IgG–related dis-
orders based on their immunogenetic background. Previous
studies have described different HLA associations in NMOSD
including subgroups of AQP4-IgG–seropositive patients. Of
interest, so far, a possible HLA association has never been
studied in MOGAD. Furthermore, HLA associations vary be-
tween ethnic backgrounds, and the Dutch AQP4-IgG-sero-
positive patients with European ancestry have never been
studied before. The aim of this study was to investigate the
possible HLA association of both MOGAD and AQP4-
IgG–positiveNMOSD in the Dutch population with European
ancestry to clarify the contribution of HLA to the pathophys-
iology in both of these diseases.
Methods
Study participants and definitions
This study was conducted at the Dutch national center for ac-
quired demyelinating syndromes, which includes the NMOSD
expert clinic (Erasmus MC) and Pediatric MS center (Erasmus
MC-Sophia Children’s Hospital) in Rotterdam, the Nether-
lands, and Sanquin Diagnostic Services in Amsterdam, the
Netherlands. Serum samples from all patients who either pre-
sented primarily at our hospitals or were referred by other (non)
academic hospitals were sent in for routine MOG-IgG and
AQP4-IgG diagnostics as part of standard clinical care. Patients
from all ages were included if they were (1) seropositive for
either MOG-IgG or AQP4-IgG and (2) of European descent.
Included patients presented with a demyelinating event within
the acquired demyelinating syndromes spectrum, i.e., ON and/
or (longitudinally extensive) transversemyelitis ([LE]TM), area
postrema syndrome, or ADEM. Diagnosis at last follow-up was
determined as NMOSD if fulfilling the Wingerchuk 2015 di-
agnostic criteria.5 Patients who had 1 or more ON following
initial presentation with ADEM were diagnosed with ADEM-
ON.13 Patients with a possible diagnosis of MS (clinically and
radiologically) were excluded.
HLA allele frequencies of MOG-IgG– and AQP4-
IgG–seropositive patients were compared with the HLA al-
lele frequencies of 5,604 healthy Dutch blood donors from the
Leiden area in the Netherlands.
Standard protocol approvals, registrations,
and patient consents
The Medical Ethical Committee of Erasmus Medical Center
in Rotterdam approved this study. All patients signed in-
formed consent to store their blood samples and clinical
characteristics in our Biobank.
Cell culture and cell-based assays
All serum sampleswere tested blindly, centrally, and in duplicate at
SanquinDiagnosticswith the cell-based assay (CBA) as previously
described.1,8 Briefly, patient serum was incubated with HEK293
cells transiently transfected with AQP4-M23 (final serum dilution
1:20) or LN18 cells stably transfected with full-lengthMOG(final
serum dilution 1:200). After washing, cells were incubated with
goat anti-human IgG allophycocyanin-conjugated secondary an-
tibody (Jackson ImmunoResearch Laboratories, Brunschwig
Chemie B.V., Amsterdam, the Netherlands [specific for human
IgG]) and analyzed using fluorescence-activated cell sorter. The
cutoff was determined in every assay as average Delta MFI +10
SDs of 8 individual sera of negative controls. Our assay comprises
an anti–IgG-specific detection antibody, and thus, no IgM anti-
MOG or IgM anti-AQP4 is detected.
HLA analysis
HLA Class I and II genotyping was performed at the National
Reference Center for Histocompatibility Testing at the De-
partment of Immunohaematology and Blood Transfusion,
Leiden University Medical Center, the Netherlands. DNA for
HLA analysis was isolated from peripheral blood samples. HLA
Class I typing (HLA-A*, -B*, -Cw*) was performed by the
reverse sequence–specific oligonucleotide (SSO) method on
a suspension array platform using microspheres as a solid
Glossary
ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; CBA = cell-based assay; HLA = human leukocyte
antigen; LETM = longitudinally extensive transverse myelitis; MOG = myelin oligodendrocyte glycoprotein; MOGAD =
myelin oligodendrocyte glycoprotein–associated disease; NMDAR = NMDA receptor; NMOSD = neuromyelitis optica
spectrum disorder; ON = optic neuritis; pc = p after correction; SSO = sequence-specific oligonucleotide; TM = transverse
myelitis.
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support to immobilize oligonucleotide probes (Luminex bead
technology; Immucor Transplant Diagnostics, Stamford, CT).
HLA Class II (HLA-DRB1*, DQB1*, DRB3*/4*/5*) was
genotyped using the PCR SSO probe technique,14 which
results in medium-low resolution subtyping.
Statistical analysis
For patient characteristic group comparisons, the χ2 or Fisher
exact test and the Mann-Whitney U test were used when
appropriate. HLA allele frequencies were analyzed using the
Fisher exact probability test. p Values were corrected with
Sidak method for multiple testing. A corrected p value (pc)
below 0.05 was considered significant. ORs were calculated
using the Woolf method with Haldane modifications (Woolf-
Haldane).
Data availability
The raw data used in this article are available at the Erasmus
University Medical Center and could be shared by request
from a qualified investigator, maintaining anonymization of
the individual patients.
Results
In total, 85 Dutch patients with European ancestry were ana-
lyzed, including 43MOG-IgG– and 42 AQP4-IgG–seropositive
patients. Patient characteristics are shown in table 1.
Patient characteristics of MOG-IgG–seropositive
patients
MOG-IgG–seropositive patients were predominantlymale (63%),
and almost half of theMOG-IgG–seropositive patients (49%) had
their onset of disease during childhood (<18 years) (table 1).
Table 1 also gives a separate overview of included children and
adults. Except for age at onset of disease, patient characteristics
were not significantly different between children and adults.
As described above, the clinical phenotype of MOGAD
consists of a spectrum of demyelinating disorders. In total, 12
MOG-IgG–seropositive patients (28%) presented with ON,
of which 42% were bilateral, and 10 (23%) with TM, of which
60% showed an longitudinally extensive lesion on MRI. In
addition, of the 7 patients (16%) presenting with a combina-
tion of ON and TM, 71% had a bilateral ON, and 67% an
LETM on MRI.
Figure 1 shows an overview of diagnosis at last follow-up of the
included MOG-IgG–seropositive patients, separated for chil-
dren and adults. Within a median follow-up of 55 months
(range: 1–463months), in total, 28% ofMOG-IgG–seropositive
patients (including 4 children and 8 adults) were finally di-
agnosed with a combination of ON and MT. Of these, only 6
patients fulfilled the Wingerchuk 2015 criteria for NMOSD di-
agnosis (50%). Only pediatric patients were diagnosed with
ADEM (62% of children vs 0% of adults, p < 0.001). Adults were
more often diagnosed with a TM compared with pediatric
patients (5% of children vs 32% of adults, p = 0.046).
Furthermore, among the MOG-IgG–seropositive patients, 1
patient was diagnosed with a progressive leukodystrophy-like
disorder with a severe regression of cognitive functions (figure
1). This patient deceased 6 years after the start of first
symptoms. Another MOG-IgG–seropositive patient pre-
sented with a recurrent encephalitis. In this patient, NMDA
receptor (NMDAR) antibodies were found additionally to the
positive MOG-IgG. This patient was diagnosed with a double
syndrome (figure 1) because besides typical anti-NMDAR
encephalitis features, this patients also had clinical and ra-
diologic findings compatible with a demyelinating disorder,
including diplopia, visual impairment, urge incontinence, and
demyelinating lesions on MRI.
Finally, 1 MOG-IgG–seropositive patient diagnosed with
monophasic ADEM also had transient AQP4-IgG; he twice
had a weak positive CBA test result for AQP4-IgG, i.e., during
onset of disease and in the first follow-up sample 5 years later.
In the following sample, 1 year later, he became AQP4-IgG
seronegative. Because theMOG-IgG remained detectable and
because of his clinical phenotype, which was more compatible
with MOGAD than AQP4-IgG–seropositive NMOSD, this
patient was only included in the MOG-IgG–seropositive pa-
tient group.
Table 1 Patient characteristics of MOG-IgG– and AQP4-IgG–seropositive patients
MOG-IgG seropositive AQP4-IgG seropositive
All patients
(n = 43)
Childrena
(n = 21)
Adultsb
(n = 22)
All patients
(n = 42)
Childrena
(n = 4)
Adultsb
(n = 38)
Female, n (%) 16 (37) 7 (33) 9 (41) 36 (86) 4 (100) 32 (84)
Age at onset, y, median (range) 24.0 (2.2–64.2) 7.8 (2.2–16.7) 36.3 (24.0–64.2) 42.0 (8.2–73.0) 11.9 (8.2–16.3) 44.9 (18.0–73.0)
Multiphasic disease, n (%) 16 (37) 8 (38) 8 (36) 28 (67) 3 (75) 25 (66)
FU duration, mo, median (range) 55 (1–463) 77 (5–463) 42 (1–260) 65 (6–312) 121 (10–153) 63 (6–312)
Abbreviations: AQP4-IgG = aquaporin-4 antibody; FU = follow-up; MOG-IgG = myelin oligodendrocyte glycoprotein antibody.
a Onset of disease <18 y of age.
b Onset of disease ≥18 y of age.
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Patient characteristics AQP4-IgG–seropositive
patients
The majority of AQP4-IgG–seropositive patients were female
(86%), and 67% of patients had a relapsing disease course
(table 1). Within a median follow-up of 65 months (range:
6–312 months), all AQP4-IgG–seropositive patients were
diagnosed with NMOSD (all fulfilling the Wingerchuk 2015
diagnostic criteria).
HLA association in MOG-IgG–seropositive
patients
In MOG-IgG–seropositive patients, a lower proportion of
HLA-A*68 (0.0% vs 9.2%, OR 0.11, 95% CI, 0.007–1.838, p =
0.0299) and a higher proportion of HLA-B*08 (41.9% vs
25.6%, OR 2.11, 95% CI, 1.154–3.842, p = 0.0217) were
observed compared with controls. However, these results did
not remain significant after statistical correction for multiple
testing (table 2). No significant HLA-A, -B, -C, -DR, and -DQ
associations were found in MOG-IgG–seropositive patients
(table e-1, links.lww.com/NXI/A214).
Because of the heterogeneity in the MOG-IgG–seropositive
patient group, different subanalyses were performed. A sub-
analysis with exclusion ofMOG-IgG–seropositive patients with
above described rare MOGAD presentations (n = 3; pro-
gressive leukodystrophy-like disorder, double syndrome with
NMDAR encephalitis, and ADEM with coexisting transient
weak positive AQP4-IgG) showed comparable results, with, in
addition, an increased frequency of HLA-DRB1*15 (40.0% vs
24.2%, OR 2.11, 95% CI, 1.127–3.949, p = 0.0260). However,
this association did not remain significant after statistical cor-
rection for multiple testing.
A subanalysis on age group, comparingMOG-IgG–seropositive
children (n = 21) with MOG-IgG–seropositive adults (n = 22),
showed no significant differences nor tendencies.
Further subanalyses in MOG-IgG–seropositive patients on dis-
ease onset phenotype (opticospinal, n = 28 vs non-opticospinal,
n = 15), disease course (monophasic, n = 27 vs multiphasic, n =
16), and final diagnosis (ADEM, n = 13 vs non-ADEM, n = 30)
showed no significant differences nor tendencies for the HLA-
A*01, -B*08, -DRB1*03 haplotype, which is the most relevant
haplotype in the European population (see below).
HLA association in AQP4-IgG–seropositive
patients
Table 3 shows significant HLA associations in the AQP4-
IgG–seropositive patients compared with controls. After
correction for multiple testing, a strong positive association
for HLA-A*01 (61.9% vs 33.7%, OR 3.16, 95% CI,
1.707–5.863, pc = 0.0045), HLA-B*08 (61.9% vs 25.6%, OR
4.66, 95% CI, 2.513–8.643, pc < 0.0001), and HLA-DRB1*03
(51.2% vs 27.6%, OR 2.75, 95%CI, 1.495–5.042, pc = 0.0199)
remained significant (figure 2), suggestive of a role of this
conserved HLA-A*01, -B*08, -DRB1*03 haplotype. In 16/42
(38%) of patients, this haplotype was present. All HLA allelic
frequencies of AQP4-IgG–seropositive patients are displayed
in table e-2 (links.lww.com/NXI/A214).
Discussion
We found clear differences in HLA Class I and II alleles in
Dutch MOG-IgG– and AQP4-IgG–seropositive patients with
European ancestry. In AQP4-IgG–seropositive patients, we
found a strong positive association with HLA-A*01, -B*08, and
-DRB1*03. In contrast, we did not find any evidence for a par-
ticular HLA association in MOG-IgG–seropositive patients.
These findings are relevant for a further distinction between
MOGAD from AQP4-IgG–positive NMOSD. Where MOG-
IgG was first found to represent a subset of patients with AQP4-
IgG–negative NMOSD, nowadays MOG-IgG is consistently
identified in a broad spectrum of acquired demyelinating syn-
dromes, which extend beyond the NMOSD phenotype.1–4,12
Previous studies have identified some clinical and imaging fea-
tures that can distinguish MOGAD from AQP4-IgG–positive
NMOSD; however, in several patients, the clinical and radiologic
phenotype still overlaps.12,15–18 Nevertheless, the immunopa-
thogenic differences in these diseases, i.e., an astrocytopathy in
AQP4-IgG–positive NMOSD and an oligodendrocytopathy in
MOGAD, suggest 2 distinctive autoimmune disorders.12 The
present findings further support these differences on the basis of
the immunogenetic features and therefore once again emphasize
the probable pathophysiologic difference between MOG-IgG–
and AQP4-IgG–related diseases.
Although HLA associations in AQP4-IgG–mediated NMOSD
have previously been studied in a few ethnic populations
Figure 1 Diagnosis at last follow-up of included
MOG-IgG–seropositive children and adults
*6/12 patients fulfilling Wingerchuk 2015 diagnostic criteria for NMOSD. **Re-
lapsing ADEM group only consists of patients with ADEM-ON (ADEM followed by
(recurrent) optic neuritis). ***Including 1 adult with a relapsing encephalitis
(double syndrome MOG-IgG/NMDA-R) and 1 child with a progressive ‘leukodys-
trophy-like’ disease. ADEM = acute disseminated encephalomyelitis; MOG-
IgG = myelin oligodendrocyte glycoprotein antibody; MOGAD = MOG-IgG-asso-
ciated disease; ON = optic neuritis; TM = transverse myelitis.
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worldwide, this study was the first investigating the Dutch
population with European ancestry. Our finding of HLA-
DRB1*03 as risk allele in AQP4-IgG–mediated disorders con-
firms and extends the results previously obtained in patients
with NMOSD from different non-Asian populations.19–24 Also,
the recent large genome-wide association study from Estrada
et al.25 found HLA-DRB1*03:01 as the most significant HLA
allele in patients with NMOSD from Texas compared with
controls of European ancestry, which was driven by the pres-
ence of AQP4-IgG. HLA-DRB1*03 has not been found as risk
allele in 2 studies with European26 and Arabic27 patients with
NMOSD. However, these 2 studies had smaller proportions of
AQP4-IgG–seropositive patients among their included patients
with NMOSD (respectively, 61% and 49%, compared with
73–100% in the other mentioned cohorts), what could explain
the absence of a significant association with HLA-DRB1*03.
An association with HLA-DPB1*0501 has previously been
described only in Asian patients with AQP4-IgG–positive
NMOSD28–30 and was not found in our Dutch patients with
European ancestry.
In addition, we found a strong correlation with HLA-A*01
(OR 3.16) and HLA-B*08 (OR 4.66): 2 HLA Class I genes.
These associations have never been described in the pre-
vious literature, possibly as most previous studies only fo-
cused on the HLA Class II alleles. AQP4-IgG has been
established as pathogenic autoantigen, directly targeting the
AQP4 water channel on the foot of the astrocytes and
causing complement-mediated necrosis, secondary de-
myelination, inflammation, and subsequently neuronal
death.9,10,31 Therefore, the expectation of HLA Class II
associations in this presumed primary B cell–mediated dis-
order is imaginable. However, also HLA Class I genes can
play a key or additional role in initiating or maintaining
autoimmune responses, primarily by triggering a CD8+ cy-
totoxic T-cell response.32 Our found associations with HLA
Class I alleles could indicate involvement of such T-cell
responses in the pathogenesis of AQP4-IgG–mediated
NMOSD. Nonetheless, HLA-A*01 and HLA-B*08 are also
known to form an ancestral European haplotype together
with (among others) HLA-DRB1*03 due to linkage.33
Whether there is an independent contribution of HLA-
A*01 and HLA-B*08 in AQP4-IgG–mediated NMOSD or
whether these HLA Class I associations are only a result of
linkage with DRB1*03 remains to be established.
Of interest, this ancestral European haplotype including HLA-
DRB1*03 has also been linked to several other autoimmune
diseases, such as SLE, Sjo¨gren syndrome, myasthenia gravis,
Graves disease, and celiac disease.32,33 This is in accordance
with the clinical observation in AQP4-IgG–seropositive
patients that around 25% of these patients have coexisting
autoimmune disorders as listed above.34–38 In our AQP4-
IgG–seropositive patients 19% also had an accompanying au-
toimmune disease.
To our best knowledge, this was the first study worldwide
investigating HLA associations in MOGAD. Of interest, we
found no evidence for particular HLA associations in
our MOG-IgG–seropositive patients. This finding is striking
because one could expect a contribution of HLA in the path-
ophysiology of MOGAD due to the presence of the autoanti-
bodies. However, in contrast to AQP4-IgG, the pathogenicity
of MOG-IgG has not fully been elucidated.15,39 MOG-IgG
targets the CNS-specific MOG protein, which is expressed on
the outer surface of the myelin sheaths and plasma membrane
of oligodendrocytes.4,40,41 Although the MOG protein only
represents a minor component of myelin (0.05%),41 its loca-
tion makes it highly immunogenic4 and is an imaginable target
for autoantibodies in a demyelinating disease. However, al-
though in vitro studies have demonstrated that human MOG-
IgG activates complement and cellular-dependent cytotoxicity,
in vivo rodent models could not confirm the humanMOG-IgG
to cause demyelination in these animals.15,42–45 Nevertheless,
there are various possible explanations for the human MOG-
IgG not being pathogenic in rodents, most importantly
because human MOG-IgG simply does not recognize the
rodent MOG protein.39 Additionally to these immuno-
logic studies, histopathologic findings from MOG-IgG–
seropositive patients show activated complement at sites of
ongoing demyelinating.39,46,47 This again supports a humoral
immune pathogenesis and a potential pathogenic activity of
human MOG-IgG.
Importantly, our negative result for HLA associations in
MOGAD does not directly reject the assumption that these
disorders are primary B cell-mediated due to the potential
T cell-independent B cell activation by antibody-inducing sig-
nals from, for example, dendritic cells, macrophages, and
granulocytes.48 An alternative explanation may be that many
different HLA Class II/peptide complexes are able to trigger
Table 2 HLA allele frequencies in MOG-IgG–seropositive patients and controlsa
Antigen
MOG-IgG Control Woolf-Haldane Fisher exact (2 sided)
Positive Negative % Positive Negative % OR 95% CI p Value pc
A*68 0 43 0.0 517 5,087 9.2 0.11 0.007–1.838 0.0299 0.4554
B*08 18 25 41.9 1,436 4,168 25.6 2.11 1.154–3.842 0.0217 0.5834
Abbreviations: HLA = human leukocyte antigen; MOG-IgG = myelin oligodendrocyte glycoprotein antibody; pc = corrected for multiple testing with the Sidak
method.
a The table shows only alleles with p < 0.05. An overview of all alleles is given in table e-1 (links.lww.com/NXI/A214).
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CD4+ T cells to provide help to the B cells resulting in IgG
antibodies in all patients irrespective of their HLA-DR type.
One could hypothesize that the distinctive clinical phenotypes
within the MOGAD could have a different underlying patho-
genesis with potentially a different immunogenetic background.
The broad spectrum of MOGAD is also variable with age at
onset. In children, ADEM is more prevalent compared with
adults. In adults, most patients have ON, (LE)TM, or both
(either simultaneously or subsequently).49 Despite these ap-
parent phenotypical differences, we did not find differences in
HLA allele frequencies when comparing subgroups regarding
age (child vs adult), disease course (mono- vs multiphasic), and
clinical presentation (opticospinal vs non-opticospinal and
ADEMvs non-ADEM), neither after exclusion of rareMOGAD
presentations. This again supports our main finding regarding
the absence of HLA association in MOGAD, with also the
absence of HLA association in distinctive MOGAD subgroups.
In general, confounding due to linkage with neighboring HLA
and non-HLA genes is a possible limitation when studying HLA
associations. Furthermore, as described before, we should be
reminiscent of the ethnic variation of HLA associations within
the same disease. We therefore only included patients with
European ancestry in our study. A specific limitation of our
study is the relatively small sample size, which is inherent to the
rarity of both antibody-mediated diseases. However, our AQP4-
IgG–seropositive patient group was very homogeneous, and
therefore, we do not expect that the relatively low number has
influenced the results in this patient group. In contrast, our
MOG-IgG–seropositive patient group wasmore heterogeneous
regarding clinical phenotype and age at onset, as a result of the
broad spectrum in MOGAD. Because of the small sample size,
only limited subanalyses were possible to overcome this issue.
In conclusion, we show no evidence for HLA association in
MOGAD in the Dutch population with European ancestry.
Whereas in AQP4-IgG–seropositive patients, the newly found
association with HLA-A*01 and HLA-B*08, together with the
confirmation of the earlier described association with HLA-
DRB1*03, is suggestive of a role of this haplotype in the
etiology of these AQP4-IgG–mediated diseases in patients
with European ancestry. These findings are suggestive of
a different immunogenetic background and therefore once
again emphasize MOGAD and AQP4-IgG–positive NMOSD
to be distinctive demyelinating disorders of the CNS.
Figure 2 Forest plot of significant HLA associations in
AQP4-IgG–seropositive patients*
*After correction for multiple testing (Sidak method).
Table 3 HLA allele frequencies in AQP4-IgG–seropositive patients and controlsa
Antigen
AQP4-IgG Control Woolf-Haldane Fisher exact (2 sided)
Positive Negative % Positive Negative % OR 95% CI p Value pc
A*01 26 16 61.9 1,887 3,717 33.7 3.16 1.707–5.863 0.0002 0.0045
A*02 13 29 31.0 2,745 2,859 49.0 0.48 0.250–0.910 0.0204 0.3379
B*08 26 16 61.9 1,436 4,168 25.6 4.66 2.513–8.643 0.0000 0.0000
C*05 0 42 0.0 764 4,840 13.6 0.07 0.005–1.212 0.0049 0.0659
C*07 32 10 76.2 3,140 2,464 56.0 2.43 1.209–4.880 0.0116 0.1504
DRB1*03b 21 20 51.2 1,524 3,990 27.6 2.75 1.495–5.042 0.0014 0.0199
DRB1*04 5 36 12.2 1,557 4,047 27.8 0.39 0.159–0.962 0.0231 0.2792
DQ8 3 38 7.3 1,073 4,462 19.4 0.38 0.126–1.131 0.0482 0.2922
DQB1*02 24 17 58.5 2,204 3,400 39.3 2.16 1.167–3.998 0.0155 0.1035
DRB4 12 29 29.3 2,608 2,996 46.5 0.49 0.251–0.945 0.0281 0.0821
Abbreviations: AQP4-IgG = aquaporin-4 antibody; pc = corrected for multiple testing with the Sidak method.
a The table shows only alleles with p < 0.05. An overview of all alleles is given in table e−2 (links.lww.com/NXI/A214).
b DRB1*03 comprises DR17.
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Similar studies need to be conducted in MOGAD, preferably
with international collaboration for larger sample sizes. Fur-
thermore, it would be interesting to investigate the in-
dependent risk of the found HLA Class I and II alleles to
AQP4-IgG–positive NMOSD.
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